Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimisation of lymph node fine needle aspiration to study pneumococcal vaccine-induced immunity
2022-501519-15-00Phase 2Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of Streptococcus pneumoniae type 19A capsular polysaccharide antigen and pneumococcal 13-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Percentage of polysaccharide-specific germinal centre B cells in lymph node aspirates. Planned start Feb 2023; status: authorised.
02
Drugs
Streptococcus pneumoniae type 19A capsular polysaccharide antigenpneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2022-501519-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501519-15-00.